Spine implant maker SI-BONE's Q3 revenue beats estimates

SI-BONE

10/11/2025 21:43

Overview

SI-BONE Q3 revenue grows 20.6% yr/yr, beating analyst expectations

Net loss for Q3 improves by 30.6% to $4.6 mln

Adjusted EBITDA turns positive at $2.3 mln in Q3

Outlook

SI-BONE expects 2025 revenue between $198 mln and $200 mln, up from prior $195 mln to $198 mln

Company estimates full-year 2025 gross margin to be ~79.5%

Result Drivers

U.S. PROCEDURE DEMAND - Strong underlying demand for procedures drove U.S. revenue growth

PHYSICIAN GROWTH - 27% increase in active U.S. physicians contributed to revenue growth

TORQ LAUNCH - International revenue growth supported by TORQ launch in Europe

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$48.66 mln
$46.70 mln (8 Analysts)
Q3 Net Income
-$4.57 mln
Q3 Gross Margin
79.80%
Q3 Basic EPS
-$0.11
Q3 Operating Expenses
$44.23 mln
Q3 Operating income
-$5.38 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for SI-BONE Inc is $25.00, about 36.9% above its November 7 closing price of $15.77

Press Release: ID:nGNX8xpMQ6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)